BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10664246)

  • 1. Truncated TSG101 transcripts in human leukemia and lymphoma cell lines.
    Hosokawa Y; Nagai E; Seto M
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):79-84. PubMed ID: 10664246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues.
    Willeke F; Ridder R; Bork P; Klaes R; Mechtersheimer G; Schwarzbach M; Zimmer D; Kloor M; Lehnert T; Herfarth C; von Knebel Doeberitz M
    Mol Carcinog; 1998 Dec; 23(4):195-200. PubMed ID: 9869447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
    Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L
    Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
    Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
    Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of TSG101 in uterine cervix cancer.
    O'Boyle JD; Proctor ML; Fong KM; Lin WM; Miller DS; Muller CY
    Gynecol Oncol; 1999 Dec; 75(3):401-5. PubMed ID: 10600297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of TSG101 transcript abnormalities in human cancers.
    Trink B; Pai SI; Spunt SL; Raman V; Cairns P; Jen J; Gabrielson E; Sukumar S; Sidransky D
    Oncogene; 1998 May; 16(21):2815-8. PubMed ID: 9652749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas.
    Liu RT; Huang CC; You HL; Chou FF; Hu CC; Chao FP; Chen CM; Cheng JT
    Oncogene; 2002 Jul; 21(31):4830-7. PubMed ID: 12101421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of cellular TSG101 protein in multiple human breast cancer cell lines.
    Zhong Q; Chen CF; Chen Y; Chen PL; Lee WH
    Cancer Res; 1997 Oct; 57(19):4225-8. PubMed ID: 9331081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines.
    Ferrer M; López-Borges S; Lazo PA
    Oncogene; 1999 Apr; 18(13):2253-9. PubMed ID: 10327071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants.
    Wagner KU; Dierisseau P; Rucker EB; Robinson GW; Hennighausen L
    Oncogene; 1998 Nov; 17(21):2761-70. PubMed ID: 9840940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.
    Carney ME; Maxwell GL; Lancaster JM; Gumbs C; Marks J; Berchuck A; Futreal PA
    J Soc Gynecol Investig; 1998; 5(5):281-5. PubMed ID: 9773405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of TSG101 tumour susceptibility gene transcripts in cervical and endometrial cancers.
    Chang JG; Su TH; Wei HJ; Wang JC; Chen YJ; Chang CP; Jeng CJ
    Br J Cancer; 1999 Feb; 79(3-4):445-50. PubMed ID: 10027311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of truncated transcripts of the proto-oncogene c-fps/fes in human lymphoma and lymphoid leukemia cell lines.
    Jücker M; Roebroek AJ; Mautner J; Koch K; Eick D; Diehl V; Van de Ven WJ; Tesch H
    Oncogene; 1992 May; 7(5):943-52. PubMed ID: 1373879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that TSG101 aberrant transcripts are PCR artifacts.
    Hampl M; Hampl J; Plaschke J; Fitze G; Schackert G; Saeger HD; Schackert HK
    Biochem Biophys Res Commun; 1998 Jul; 248(3):753-60. PubMed ID: 9704000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 induction prevents accumulation of aberrant transcripts in cancer cells.
    Moyret-Lalle C; Duriez C; Van Kerckhove J; Gilbert C; Wang Q; Puisieux A
    Cancer Res; 2001 Jan; 61(2):486-8. PubMed ID: 11212237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant splicing of FHIT transcripts in human gastric cancer cell lines.
    Lee SH; Kim HY; Kim TJ; Park HK; Kim WH; Woo KM; Cho MH
    Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):39-49. PubMed ID: 15080495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of human endogenous retrovirus k envelope transcripts in human breast cancer.
    Wang-Johanning F; Frost AR; Johanning GL; Khazaeli MB; LoBuglio AF; Shaw DR; Strong TV
    Clin Cancer Res; 2001 Jun; 7(6):1553-60. PubMed ID: 11410490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [TSG101 and breast cancer: a correctly named tumor-suppressor gene?].
    Bénard J; Ahomadégbé JC
    Bull Cancer; 1997 Dec; 84(12):1141-2. PubMed ID: 9587367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.
    Yamada M; Asanuma K; Kobayashi D; Moriai R; Yajima T; Yagihashi A; Yamamori S; Watanabe N
    Anticancer Res; 2001; 21(1B):633-8. PubMed ID: 11299818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.